Unigene Laboratories, Inc. Release: Independent Advisory Committee Recommends Continuation of Phase III Oral Calcitonin Studies for Osteoporosis and Osteoarthritis

BOONTON, N.J.--(BUSINESS WIRE)--Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) announced that an independent Data Monitoring Committee (DMC) has recommended that Novartis and its partner Nordic Bioscience proceed as planned with their ongoing oral calcitonin Phase III studies for osteoporosis and osteoarthritis.